JP2011527696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011527696A5 JP2011527696A5 JP2011517605A JP2011517605A JP2011527696A5 JP 2011527696 A5 JP2011527696 A5 JP 2011527696A5 JP 2011517605 A JP2011517605 A JP 2011517605A JP 2011517605 A JP2011517605 A JP 2011517605A JP 2011527696 A5 JP2011527696 A5 JP 2011527696A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- hydrogen
- formula
- protecting group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000006239 protecting group Chemical group 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 3
- 239000011612 calcitriol Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- AEDMQUAPBVOJNN-UHFFFAOYSA-N [3-[2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-5-yl]methanol Chemical compound O1C(CO)=NC(C=2SC(=NC=2)N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)=N1 AEDMQUAPBVOJNN-UHFFFAOYSA-N 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000006409 renal osteodystrophy Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000002374 sebum Anatomy 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 230000037393 skin firmness Effects 0.000 claims 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
- ROBWDHHBRICTRR-CTIJHLJASA-N CC(C)(CCC/C=C(/CC1)\[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(C[C@H](C1=C)O)C[C@H]1O)O Chemical compound CC(C)(CCC/C=C(/CC1)\[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(C[C@H](C1=C)O)C[C@H]1O)O ROBWDHHBRICTRR-CTIJHLJASA-N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/171,071 US7893043B2 (en) | 2008-07-10 | 2008-07-10 | 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs |
| US12/171,071 | 2008-07-10 | ||
| PCT/US2009/050060 WO2010006135A2 (en) | 2008-07-10 | 2009-07-09 | 2-methylene-(17z)-17(20)-dehydro-19,21-dinor-vitamin d analogs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011527696A JP2011527696A (ja) | 2011-11-04 |
| JP2011527696A5 true JP2011527696A5 (enExample) | 2012-08-23 |
| JP5629682B2 JP5629682B2 (ja) | 2014-11-26 |
Family
ID=41382492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517605A Expired - Fee Related JP5629682B2 (ja) | 2008-07-10 | 2009-07-09 | ２−メチレン−（１７ｚ）−１７（２０）−デヒドロ−１９，２１−ジノル−ビタミンｄ類似物質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7893043B2 (enExample) |
| EP (1) | EP2313368B1 (enExample) |
| JP (1) | JP5629682B2 (enExample) |
| AU (1) | AU2009268567B2 (enExample) |
| CA (1) | CA2730254C (enExample) |
| MX (1) | MX2011000357A (enExample) |
| WO (1) | WO2010006135A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8404667B2 (en) * | 2006-12-29 | 2013-03-26 | Wisconsin Alumni Research Foundation | Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog |
| US20110237557A1 (en) * | 2010-03-23 | 2011-09-29 | Deluca Hector F | Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3 |
| US8664206B2 (en) | 2010-03-23 | 2014-03-04 | Wisconsin Alumni Research Foundation | Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3 |
| US8604009B2 (en) * | 2010-03-23 | 2013-12-10 | Wisconsin Alumni Research Foundation | (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666634A (en) * | 1984-12-05 | 1987-05-19 | Chugai Seiyaku Kabushiki Kaisha | vitamin D3 derivatives having a substituent at 2-position |
| US5086191A (en) * | 1991-05-28 | 1992-02-04 | Wisconsin Alumni Research Foundation | Intermediates for the synthesis of 19-nor vitamin D compounds |
| GB9214202D0 (en) | 1992-07-03 | 1992-08-12 | Leo Pharm Prod Ltd | Chemical compounds |
| JP2898882B2 (ja) * | 1993-04-05 | 1999-06-02 | ウイスコンシン アラムナイ リサーチ フオンデーシヨン | ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物 |
| US5552392A (en) * | 1993-11-03 | 1996-09-03 | Wisconsin Alumni Research Foundation | Method of treating hypoparathyroidism with (20S) vitamin D compounds |
| DK0717034T3 (da) * | 1994-12-14 | 1999-10-18 | Duphar Int Res | Vitamin D-forbindelser og fremgangsmåde til fremstilling af disse forbindelser |
| GB9625271D0 (en) | 1996-12-04 | 1997-01-22 | Leo Pharm Prod Ltd | Chemical compounds |
| US5945410A (en) * | 1997-03-17 | 1999-08-31 | Wisconsin Alumni Research Foundation | 2-alkyl-19-nor-vitamin D compounds |
| US5843928A (en) * | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| US6392071B1 (en) * | 1997-03-17 | 2002-05-21 | Wisconsin Alumni: Research Foundation | 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds |
| US6316642B1 (en) * | 1997-03-17 | 2001-11-13 | Wisconsin Alumni Research Foundation | 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds |
| US6306844B1 (en) * | 1997-03-17 | 2001-10-23 | Wisconsin Alumni Research Foundation | Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength |
| GB9721156D0 (en) | 1997-10-06 | 1997-12-03 | Leo Pharm Prod Ltd | Novel vitamin d analogues |
| US6806262B2 (en) * | 2000-05-31 | 2004-10-19 | Wisconsin Alumni Research Foundation | 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds |
| AU7544501A (en) * | 2000-09-08 | 2002-03-22 | Wisconsin Alumni Res Found | 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications |
| US6627622B2 (en) * | 2002-02-18 | 2003-09-30 | Wisconsin Alumni Research Foundation | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
| US6566352B1 (en) * | 2002-02-18 | 2003-05-20 | Wisconsin Alumni Research Foudation | 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses |
| ATE346839T1 (de) * | 2002-03-29 | 2006-12-15 | Wisconsin Alumni Res Found | Ein verfahren zur herstellung von 1-alpha-hydroxy-2-methylen-19-nor-homopregnacal iferol |
| US6846811B2 (en) * | 2002-04-22 | 2005-01-25 | Wisconsin Alumni Research Foundation | (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses |
| WO2005051323A2 (en) | 2003-11-25 | 2005-06-09 | Wisconsin Alumni Research Foundation | Vitamin d analogs for obesity prevention and treatment |
| AU2005309806B2 (en) * | 2004-11-22 | 2012-03-08 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses |
| ATE523487T1 (de) * | 2006-04-06 | 2011-09-15 | Wisconsin Alumni Res Found | 2-methylen-1-alpha-dihydroxy-19,21-dinor-vitami - d3-analoga und ihre anwendung |
-
2008
- 2008-07-10 US US12/171,071 patent/US7893043B2/en not_active Expired - Fee Related
-
2009
- 2009-07-09 WO PCT/US2009/050060 patent/WO2010006135A2/en not_active Ceased
- 2009-07-09 EP EP09790206.8A patent/EP2313368B1/en not_active Ceased
- 2009-07-09 CA CA2730254A patent/CA2730254C/en not_active Expired - Fee Related
- 2009-07-09 AU AU2009268567A patent/AU2009268567B2/en not_active Ceased
- 2009-07-09 JP JP2011517605A patent/JP5629682B2/ja not_active Expired - Fee Related
- 2009-07-09 MX MX2011000357A patent/MX2011000357A/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010505739A5 (enExample) | ||
| JP2008520689A5 (enExample) | ||
| JP2009532458A5 (enExample) | ||
| JP2008520703A5 (enExample) | ||
| TWI598098B (zh) | 脂質異常症治療劑 | |
| JP2010504995A5 (enExample) | ||
| JP2005529878A5 (enExample) | ||
| JP2011527699A5 (enExample) | ||
| JP2011527695A5 (enExample) | ||
| JP2008520691A5 (enExample) | ||
| JP2008520705A5 (enExample) | ||
| US8501806B2 (en) | Methods for preventing or reducing colon carcinogenesis | |
| WO2012009258A3 (en) | Peptidomimetic galanin receptor modulators | |
| JP2011527696A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2008520704A5 (enExample) | ||
| JP2010504994A5 (enExample) | ||
| JP2008530110A5 (enExample) | ||
| CA2588415A1 (en) | 2-methylene-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and its uses | |
| JP2013522369A5 (enExample) | ||
| JP2008520716A5 (enExample) | ||
| JP2008520709A5 (enExample) | ||
| JP2008520706A5 (enExample) | ||
| JP2019167351A (ja) | 癌治療 | |
| JP2009533483A5 (enExample) |